Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Más betegség

• Target Disease Exceptions:
  • Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply

• Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
• Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
• Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
• ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
• Evidence of plaque psoriasis in a non-scalp area
• Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis